Expectant mothers are considered to be at high risk when it comes to COVID-19, but they also fall into an uncertain category for receiving the vaccination against the disease since they were not part of initial clinical trials.
Pfizer is now planning to enroll 4,000 pregnant women from the U.S. and several other countries in a new trial to study the effects of the vaccine. Women over the age of 18 and between 24 to 34 weeks into their pregnancy will be eligible. Some of the women will get the real vaccine while others will get a placebo.
So far, experts say pregnant women who already were vaccinated did not show any red flags. But the potential risks to the mother and fetus are unknown due to the lack of studies.